ArticleClinical and experimental nephrology2023
Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.
Article in Clinical and experimental nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 9 citations in OpenAlex.
- Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial).Clinical and experimental nephrology · 2024Trial
- When should sequential rituximab therapy for long-term B-cell depletion be initiated in children with steroid-sensitive nephrotic syndrome?Pediatric nephrology (Berlin, Germany) · 2026Article
- Hypogammaglobulinemia and B cell repopulation after rituximab in childhood nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Optimal selection and timing of steroid-sparing therapy in childhood nephrotic syndrome: what determines long-term outcomes of adult survivors?Pediatric nephrology (Berlin, Germany) · 2026Article
- [Efficacy and safety of rituximab in children with refractory nephrotic syndrome].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Comparison of efficacy of single-dose and double-dose rituximab in the treatment of refractory nephrotic syndrome in children: a retrospective study.Pediatric nephrology (Berlin, Germany) · 2026Article
- Response to Fujinaga - discontinuing immunosuppression in idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2025Article
- Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab.Clinical and experimental nephrology · 2024Article
- Changes in adverse events after multiple rituximab courses in patients with complicated steroid-dependent nephrotic syndrome.Clinical and experimental nephrology · 2024Article
- Identification of Risk Factors for Relapse following Rituximab Therapy in Children with Steroid-Sensitive Nephrotic Syndrome.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the fact that rituximab (RTX)-associated adverse events may be relatively frequent in younger patients, recent studies have reported RTX as a suitable first-line steroid-sparing agent for maintaining remission in children with steroid-dependent nephrotic syndrome (SDNS). However, the impact of age at RTX initiation on the long-term outcome remains unknown in this cohort.
methodsWe retrospectively reviewed the clinical course of 61 patients with complicated SDNS who received a single dose of RTX (375 mg/m
resultsAfter RTX initiation, 52 patients (85.2%) relapsed after a median of 665 days, and 44 patients (72.1%) received additional RTX doses (total, 226 infusions). At the last follow-up (median observation period, 8.3 years; median age, 18.3 years), 16 patients (26.2%) achieved long-term remission. Multivariate analysis showed that older age at RTX initiation was the independent predictive factor for achieving long-term remission (odds ratio, 1.25; p < 0.05). The proportion of those who achieved long-term remission was significantly higher in patients aged ≥ 13.5 years than in those aged < 13.5 years at RTX initiation (52.6 vs 14.3%, p < 0.05). Persistent severe hypogammaglobulinemia did not develop in older children (≥ 13.5 years) at RTX initiation.
conclusionFor older children with complicated SDNS, RTX appeared to be a suitable disease-modifying therapy without persistent adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.